Dr Hamid speaks with ecancertv at ESMO 2016 about the outcomes of a phase I study into the responses to combined PD-1 and PD-L1 inhibition in multiple tumour sites.
PD-1 and PD-L1 have been targets of immune checkpoint inhibitor therapy independently across multiple cancer types and sites, and Dr Hamid describes the initial results of co-targeting both at once.
He introduces upcoming phase II trials in bladder cancer, and considers how to improve patient responses for those expressing either high or low levels of the biomarkers.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.